ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nerandomilast

Also written as “BI 1015550”, “Nerandomilast” and “Nerandomilast formulation 1”.

Its studies are mostly in Lung Diseases, Interstitial · Idiopathic Pulmonary Fibrosis · Myositis · Scleroderma, Systemic · Amyotrophic Lateral Sclerosis, led by 2 companies.

Drug pageNerandomilast: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 4, 202235 company-led studies, 8 open or runningNext primary completion: Apr 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim347 open or runningphase 3since Apr 4, 2022May 7, 2012Apr 15, 2027phase 3 · NCT06806592
Gipfel Life Sciencesits history only11 open or runningphase 3since Jan 2, 2026Jan 2, 2026Jun 30, 2027phase 3 · NCT07321860

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 17 studies since May 7, 2012.

  1. Aug 6, 2023Named nerandomilastINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BI 1015550
  2. Oct 2, 20232 phase 1 studies in HealthyNCT06070610, NCT06107036
  3. Nov 15, 2023Phase 1 study in HealthyNCT06139302 · 12 enrolled · Japan
  4. Jan 25, 2024Phase 3 study in Idiopathic Pulmonary FibrosisNCT06238622 · 1,666 enrolled · United States, Argentina, Australia and more
  5. Jan 29, 2024Phase 2 study in Idiopathic Pulmonary FibrosisNCT06241560 · 20 enrolled · United States, Georgia
  6. Apr 29, 2024Phase 1 study in HealthyNCT06393127 · 64 enrolled · Germany
  7. May 7, 20242 phase 1 studies in HealthyNCT06408870, NCT06415045
  8. Oct 1, 2024Phase 1 study in HealthyNCT06624072 · 15 enrolled · Germany
  9. Jan 28, 2025Phase 3 study in Lung Diseases, InterstitialNCT06806592 · 414 enrolled · United States, Australia, Austria and more
  10. Jul 22, 20252 phase 1 studies in HealthyNCT07081932, NCT07100964
  11. Sep 30, 2025Phase 3 study in Lung Diseases, InterstitialNCT07201922 · 80 planned · United States, Argentina, Australia and more
  12. Jan 23, 2026Phase 3 study in Fibrosing Interstitial Lung DiseaseNCT07366034 · 35 planned · United States, Argentina, Australia and more
  13. Mar 23, 2026Phase 3 study in Scleroderma, SystemicNCT07497087 · 448 planned · United States, Argentina, Australia and more
  14. Apr 15, 2026Phase 3 study in Lung Diseases, InterstitialNCT07540988 · 466 planned · United States, Argentina, Australia and more
  15. Aug 24, 2026Phase 3 study in MyositisNCT07789015 · 270 planned · United States, Argentina, Australia and more

Ahead

  1. Apr 15, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialNCT06806592
  2. Apr 28, 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT06238622
  3. Dec 5, 2028Primary completion: phase 3 study in Lung Diseases, InterstitialNCT07540988
  4. Apr 27, 2029Primary completion: phase 3 study in Fibrosing Interstitial Lung DiseaseNCT07366034

TargetBeta

PDE4B →read by rule
“Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades.”study text, by rule · the study

Other programs on PDE4B

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
difamilastruleOtsukaphase 316
tanimilastruleChiesi Farmaceuticiphase 315

Studies

All 34 Boehringer Ingelheim leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07789015Myositis · United States, Argentina, Australia and more3Not yet recruitingMar 21, 2030270
NCT07540988Lung Diseases, Interstitial · United States, Argentina, Australia and more3RecruitingDec 5, 2028466
NCT07497087Scleroderma, Systemic · United States, Argentina, Australia and more3RecruitingFeb 26, 2030448
NCT07366034Fibrosing Interstitial Lung Disease · United States, Argentina, Australia and more3RecruitingApr 27, 202935
NCT07201922Lung Diseases, Interstitial · United States, Argentina, Australia and more3RecruitingMay 14, 202980
NCT07100964Healthy · Germany1CompletedSep 20, 202516
NCT07081932Healthy · Germany1CompletedSep 27, 202516
NCT06806592Lung Diseases, Interstitial · United States, Australia, Austria and more3Active, not recruitingApr 15, 2027414
NCT06624072Healthy · Germany1CompletedNov 22, 202415
NCT06415045Healthy · Germany1CompletedJul 24, 202418
NCT06408870Healthy · Germany1CompletedAug 28, 202464
NCT06393127Healthy · Germany1CompletedSep 10, 202464
NCT06241560Idiopathic Pulmonary Fibrosis · United States, Georgia2CompletedAug 5, 202620
NCT06238622Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more3Active, not recruitingApr 28, 20271,666
NCT06139302Healthy · Japan1CompletedFeb 7, 202412
NCT06107036Healthy · United Kingdom1CompletedJul 25, 202446
NCT06070610Healthy · Germany1CompletedDec 14, 202314
NCT05718648Renal Insufficiency · Germany1CompletedAug 15, 202326
NCT05707403Healthy · Netherlands1CompletedMar 28, 20238
NCT05661344Hepatic Insufficiency · Germany1CompletedSep 13, 202328
NCT05633862Healthy · China1CompletedMar 16, 202324
NCT05550636Healthy · Germany1CompletedDec 19, 202215
NCT05428436Healthy · Germany1CompletedSep 30, 202224
NCT05321082Lung Diseases, Interstitial · United States, Argentina, Australia and more3CompletedDec 18, 20241,178
NCT05321069Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more3CompletedAug 16, 20241,177
NCT04771286Healthy · Netherlands1CompletedMay 17, 20216
NCT04419506Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more2CompletedOct 6, 2021147
NCT03542344Healthy · Japan1CompletedAug 24, 201816
NCT03422068Idiopathic Pulmonary Fibrosis · Denmark, Finland, Germany and more1CompletedJul 1, 201915
NCT03403439Healthy · Germany1CompletedJul 20, 201816
NCT03302078Healthy · Germany1CompletedDec 13, 201712
NCT03230487Healthy · Germany1CompletedJan 16, 201842
NCT01835899Healthy · Germany1CompletedJun 201324
NCT01594515Healthy · Germany1CompletedSep 201270

How it is read

Names in the registry

  • “BI 1015550”, 27 entries
  • “Nerandomilast”, 10 entries
  • “Nerandomilast formulation 1”, 1 entry
  • “Nerandomilast formulation 2”, 1 entry
  • “Nerandomilast 18 mg - adult formulation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.